Skip to main content

Advertisement

Table 1 Clinical features of the 569 patients registered in the ORA and included in the present study

From: Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry

  Abatacept monotherapy (n = 188) Abatacept + DMARDs (n = 381)
Sex, female n (%) 153 (81 %) 297 (78 %)
Age, median (range) 63 (22–89) 59 (23–89)
Duration of disease, median (range) 16 (3–51) 14 (2–45)
Inclusion DAS-28 score, median (range) 5.5 (2–8.9) 5.3 (1.6–8.5)
Previous anti-TNF therapy, n (%)   
 0 26 (14 %) 38 (10 %)
 1 47 (25 %) 85 (22 %)
 2 72 (38 %) 156 (41 %)
 3 43 (23 %) 102 (27 %)
Previous rituximab therapy, n (%) 72 (38 %) 104 (27 %)
Cortisone treatment, n (%) 144 (75 %) 280 (73 %)
Rheumatoid factor, n (%) 73/86 (85 %) 133/155 (86 %)
ACPA, n (%) 67/71 (94 %) 112/124 (90 %)
C-reactive protein, median (range) 14 (0.2–157) 12 (0–179)
Smoking, n (%) 18 (9 %) 49 (13 %)
  1. DMARDs disease-modifying anti-rheumatic drugs, DAS-28 28-item Disease Activity Score, TNF tumour necrosis factor, ACPA anti-citrullinated peptide antibody